glycogen storage disease/rasvumus

Link salvestatakse lõikelauale

Artiklid Kliinilistes uuringutesPatendid

Valige sortimise tüüp

Leht 1 alates 33 tulemused

Obesity and reversed growth retardation in a child with type Ia glycogen storage disease.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Type Ia Glycogen storage disease is an autosomal recessive hepatic metabolic disease due to a lack of glucose-6-phosphatase (G-6-Pase) activity presenting with growth retardation, lactic acidosis, fasting hypoglycemia with hypoinsulinemia, hyperuricemia, hepatomegaly, and hepatic adenoma with a risk

Continuous glucose monitoring in the treatment of obesity in patients with glycogen storage disease type Ia.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Glycogen storage disease (GSD) type I is characterized by impaired production of glucose from glycogenolysis and gluconeogenesis resulting in severe hypoglycaemia and increased production of lactic acid, triglyceride and uric acid. The most common type, glycogenosis type Ia, demands a balanced,

Bariatric surgery is not contraindicated in obese patients suffering from glycogen storage disease type IXa. A case report with follow-up at three years.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Glucose storage disease type IXa (GSD IXa) is an uncommon condition presenting with childhood onset hepatomegaly, growth retardation, and often, fasting ketosis and hypoglycemia. Despite its benign course, the lack of dietary counseling may favor uncontrolled weight gain. We investigated

Familial cardiac glycogen storage disease; associated hereditary maternal diabetes mellitus and obesity.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Glycogen storage disease type I: clinical and laboratory profile.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE To characterize the clinical, laboratory, and anthropometric profile of a sample of Brazilian patients with glycogen storage disease type I managed at an outpatient referral clinic for inborn errors of metabolism. METHODS This was a cross-sectional outpatient study based on a convenience

Fatty Liver Caused by Glycogen Storage Disease Type IX: A Small Series of Cases in Children.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The prevalence of non-alcoholic fatty liver disease (NAFLD) affecting children and adolescents has increased dramatically in recent years. This increase is most probably related to the obesity pandemic and the high consumption of fructose. However, hepatic steatosis has some rare

Glucose therapy for glycogenosis type 1 in infants: comparison of intermittent uncooked cornstarch and continuous overnight glucose feedings.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

This study was undertaken to test the glycemic response of five infants with glycogen storage disease type 1, aged 0.7 to 1.5 years, to uncooked cornstarch under various dietary conditions, and to evaluate the long-term effects of a dietary regimen consisting of uncooked cornstarch in milk every 4

Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Glycogen storage disease type-Ia (GSD-Ia) is caused by a lack of glucose-6-phosphatase-α (G6Pase-α or G6PC) activity. We have shown that gene therapy mediated by a recombinant adeno-associated virus (rAAV) vector expressing human G6Pase-α normalizes blood glucose homeostasis in the global G6pc

Glycogen storage disease presenting as Cushing syndrome.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Impaired growth is common in patients with glycogen storage disease (GSD), who also may have "cherubic" facies similar to the "moon" facies of Cushing syndrome (CS). An infant presented with moon facies, growth failure, and obesity. Laboratory evaluation of the

Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Glycogen storage disease type Ia (GSD-Ia), characterized by impaired glucose homeostasis and chronic risk of hepatocellular adenoma (HCA) and carcinoma (HCC), is caused by a deficiency in glucose-6-phosphatase-α (G6Pase-α or G6PC). We have previously shown that G6pc-/- mice receiving gene transfer

Living donor liver transplantation for glycogen storage disease type Ib.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Glycogen storage disease type 1b (GSD-1b) is due to an autosomal recessive inborn error of carbohydrate metabolism caused by defects in glucose-6-phosphatase translocase. Patients with GSD-1b have severe hypoglycemia with several clinical manifestations of hepatomegaly, obesity, a doll-like face,

Usefulness of chemical-shift MRI in discriminating increased liver echogenicity in glycogenosis.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Glycogen storage diseases are inherited defects which cause accumulation of glycogen in the tissues. Hepatic steatosis is defined as accumulation of fat within hepatocytes. On sonography, liver shows increased echogenicity both in glycogen storage diseases and steatosis. Liver

Hepatic glycogen storage diseases are associated to microbial dysbiosis.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The gut microbiome has been related to several features present in Glycogen Storage Diseases (GSD) patients including obesity, inflammatory bowel disease (IBD) and liver disease.The primary objective of this study was to investigate associations between GSD

Liver-directed gene therapy for murine glycogen storage disease type Ib.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Glycogen storage disease type-Ib (GSD-Ib), deficient in the glucose-6-phosphate transporter (G6PT), is characterized by impaired glucose homeostasis, myeloid dysfunction, and long-term risk of hepatocellular adenoma (HCA). We examined the efficacy of G6PT gene therapy in G6pt-/- mice using

Long-term Outcomes of Living Donor Liver Transplantation for Glycogen Storage Disease Type 1b.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Glycogen storage disease (GSD) type 1b (OMIM 232220) is an autosomal recessive inborn error of carbohydrate metabolism caused by defects in glucose-6-phosphatase translocase (G6PT). GSD1b patients have severe hypoglycemia with several clinical manifestations of hepatomegaly, obesity, a doll-like

Eelmine
1
2
3
Järgmine

Liitu meie
facebooki lehega

Herbal & Natural Medicine

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

Töötab 55 keeles
Taimsed ravimid, mida toetab teadus
Maitsetaimede äratundmine pildi järgi
Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
Lugege oma otsinguga seotud teaduspublikatsioone
Otsige ravimtaimi nende mõju järgi
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel